Plasmacytoma
12
1
3
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
25.0%
3 terminated out of 12 trials
62.5%
-24.0% vs benchmark
8%
1 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma
Phase I/II Study of hLL1 in Multiple Myeloma
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma